Lallemand C - Search Results

1

Safety, Tolerability, and Immunogenicity of Interferons.

Tovey MG, Lallemand C. Tovey MG, et al. Among authors: lallemand c. Pharmaceuticals (Basel). 2010 Apr 20;3(4):1162-1186. doi: 10.3390/ph3041162. Pharmaceuticals (Basel). 2010. PMID: 27713294 Free PMC article. Review.

2

Adjuvant activity of type I interferons.

Tovey MG, Lallemand C, Thyphronitis G. Tovey MG, et al. Among authors: lallemand c. Biol Chem. 2008 May;389(5):541-5. doi: 10.1515/bc.2008.051. Biol Chem. 2008. PMID: 18953720 Review.

3

Immunogenicity and other problems associated with the use of biopharmaceuticals.

Tovey MG, Lallemand C. Tovey MG, et al. Among authors: lallemand c. Ther Adv Drug Saf. 2011 Jun;2(3):113-28. doi: 10.1177/2042098611406318. Ther Adv Drug Saf. 2011. PMID: 25083207 Free PMC article. Review.

4

Adjuvant activity of interferon alpha: mechanism(s) of action.

Tovey MG, Lallemand C, Meritet JF, Maury C. Tovey MG, et al. Among authors: lallemand c. Vaccine. 2006 Apr 12;24 Suppl 2:S2-46-7. doi: 10.1016/j.vaccine.2005.01.117. Vaccine. 2006. PMID: 16823922

5

Adjuvant activity of cytokines.

Tovey MG, Lallemand C. Tovey MG, et al. Among authors: lallemand c. Methods Mol Biol. 2010;626:287-309. doi: 10.1007/978-1-60761-585-9_19. Methods Mol Biol. 2010. PMID: 20099135 Review.

6

One-step assay for quantification of neutralizing antibodies to biopharmaceuticals.

Lallemand C, Meritet JF, Blanchard B, Lebon P, Tovey MG. Lallemand C, et al. J Immunol Methods. 2010 Apr 30;356(1-2):18-28. doi: 10.1016/j.jim.2010.03.003. Epub 2010 Mar 15. J Immunol Methods. 2010. PMID: 20298696

7

Overcoming immunogenicity associated with the use of biopharmaceuticals.

Tovey MG, Legrand J, Lallemand C. Tovey MG, et al. Among authors: lallemand c. Expert Rev Clin Pharmacol. 2011 Sep;4(5):623-31. doi: 10.1586/ecp.11.39. Expert Rev Clin Pharmacol. 2011. PMID: 22114889 Review.

8

Constitutive expression of specific interferon isotypes in peripheral blood leukocytes from normal individuals and in promonocytic U937 cells.

Lallemand C, Lebon P, Rizza P, Blanchard B, Tovey MG. Lallemand C, et al. J Leukoc Biol. 1996 Jul;60(1):137-46. doi: 10.1002/jlb.60.1.137. J Leukoc Biol. 1996. PMID: 8699118

9

Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB.

Lallemand C, Blanchard B, Palmieri M, Lebon P, May E, Tovey MG. Lallemand C, et al. Oncogene. 2007 Jan 18;26(3):328-38. doi: 10.1038/sj.onc.1209795. Epub 2006 Jul 10. Oncogene. 2007. PMID: 16832344

10

Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.

Lallemand C, Meritet JF, Erickson R, Grossberg SE, Roullet E, Lyon-Caen O, Lebon P, Tovey MG. Lallemand C, et al. J Interferon Cytokine Res. 2008 Jun;28(6):393-404. doi: 10.1089/jir.2007.0142. J Interferon Cytokine Res. 2008. PMID: 18593334

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page